Biopharmaceutical Company Announces First Patient Dosed In Cancer Treatment Trial
Verastem Oncology Announces First Patient Dosed in Phase 1/2 Trial of GFH375/VS-7375 in China.
Disclaimer: The following article is for informational purposes only and should not be considered as medical advice. All information provided is based on recent announcements and data pertaining to the development of GFH375/VS-7375 by Verastem Oncology and GenFleet Therapeutics. Readers should consult with healthcare professional…